Trogenix is a biotech company that develops precision cancer treatments that selectively target diseased cell states and behaviour.
Trogenix has raised $94.1M in total funding. The most recent round was Series A. The last funding was announced in October 2025.
Trogenix's investors include IQ Capital, Eli Lilly, AIN Ventures, 4BIO Capital, LongeVC.
Trogenix is headquartered in Edinburgh, United Kingdom.
Trogenix is a biotech company that develops precision cancer treatments that selectively target diseased cell states and behaviour.
Trogenix is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Trogenix — Funding & Investors." VCBacked, October 6, 2025, https://www.vcbacked.co/company/trogenix. Accessed September 30, 2026.
VCBacked. (2025). Trogenix — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/trogenix
{{cite web |title=Trogenix — Funding & Investors |url=https://www.vcbacked.co/company/trogenix |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated